BNP Paribas downgraded Roche (RHHBY) to Neutral from Outperform with a $50 price target The firm cut the company’s estimates following its recent pipeline updates. Roche’s major clinical updates are not coming until 2027, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- District court rules federal limits to vaccines not based on science, NYT says
- Piper Sandler biotech analysts hold analyst/industry conference call
- Roche receives CE Mark for Elecsys Apolipoprotein E4 test
- Roche price target lowered to CHF 325 from CHF 350 at JPMorgan
- Xencor reports receipt of notice of termination of license agreement from Roche